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There is considerable evidence that circadian rhythms in mammals 
can be modulated by emotional state, but how emotional state 
modulates specific circadian outputs is poorly understood. We 
analyzed the expression of the circadian clock protein Period2 
(PER2) in three regions of the limbic forebrain known to play key 
roles in emotional regulation, the central nucleus of the amygdala 
(CEA), the basolateral amygdala (BLA), and the dentate gyrus (DG). 
We report here that cells in all three regions exhibit daily rhythms 
in expression of PER2 that are under the control of the master clock, 
the suprachiasmatic nucleus (SCN). The rhythm in the CEA and the 
rhythms in the BLA and DG are diametrically opposite in phase and 
are differentially affected by adrenalectomy. Adrenalectomy completely 
abolished the PER2 rhythm in the CEA but had no effect on 
the PER2 rhythms in the BLA and DG. We previously reported a 
rhythm in PER2 expression in the oval nucleus of the bed nucleus 
of the stria terminalis that is identical in phase and sensitivity to 
adrenalectomy to that found in the CEA. Together, these findings 
show that key structures of the limbic forebrain exhibit daily 
oscillations in clock gene expression that are controlled not only by 
input from the SCN but, importantly, by hormonal and neurochemical 
changes that normally accompany motivational and emotional 
states. Thus, cells within these areas are strategically positioned to 
integrate the inputs from the SCN and emotional states to modulate 
circadian rhythms downstream from the SCN clock. 
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In mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus 
is recognized as a master clock responsible for the 
regulation of all behavioral and physiological circadian rhythms 
(1). The rhythm of the SCN, although sensitive to the daily cycle 
of light, is relatively invulnerable to environmental challenges 
and changes in physiology (2, 3). Yet it is recognized that 
stressors and changes in emotional states can have disruptive 
effects on behavioral and physiological rhythms (4–8). Furthermore, 
disruptions of circadian rhythms have negative effects on 
mood and well being, as observed during jet lag or shift work 
(9, 10). 
Although the SCN is the only clock structure required for the 
generation of circadian rhythmicity, recent studies show that 
circadian rhythms in expression of clock genes, such as Per1 and 
Per2, can be found in other brain regions that participate in the 
control of specific behavioral and physiological outputs. These 
include, but are not limited to, the striatum, paraventricular 
hypothalamic nucleus, arcuate nucleus, preoptic area, and olfactory 
bulbs (11–17). The study of clock genes in these and other 
functionally defined brain regions may help to determine how 
the SCN clock controls specific circadian rhythms and, importantly, 
may contribute to an understanding of how diverse 
experiences and pathological conditions can affect circadian 
rhythms downstream from the SCN clock. 
We found recently that the clock protein Period2 (PER2) is 
expressed rhythmically in the oval nucleus of the bed nucleus of 
the stria terminalis (BNST-OV) (18), a region of the limbic 
forebrain known to be involved in the regulation of behavioral, 
autonomic, and endocrine responses to motivationally and emotionally 
significant stimuli (19, 20). This rhythm was synchronous 
with the PER2 rhythm in the SCN and was maintained in 
constant dark. Furthermore, both lesions of the SCN that 
abolished circadian locomotor activity rhythms and adrenalectomy 
completely dampened the PER2 rhythm in the BNST-OV. 
Based on these findings, we concluded that the BNST-OV 
contains circadian oscillators that could serve as an interface 
between the output of the SCN clock and emotional and 
motivational states (18). 
The amygdala is another region of the limbic forebrain 
importantly involved in the control of motivational and emotional 
states (21–23). Anatomically, the amygdala is subdivided 
into a number of distinct areas, of which two are particularly 
important in the regulation of motivational and emotional 
processes: the basolateral amygdala (BLA) and the central 
nucleus of the amygdala (CEA) (21, 23–27). In view of our 
findings in the BNST-OV, it was of interest, therefore, to 
determine whether these regions of the amygdala might also 
exhibit daily rhythms of expression of PER2. Furthermore, we 
assess the expression of PER2 in the dentate gyrus (DG), a 
region of the hippocampus that is heavily influenced by the BLA 
(28, 29) and that has been implicated in emotional memory. 
Materials and Methods 
Animals and Housing. The experimental procedures followed the 
guidelines of the Canadian Council on Animal Care and were 
approved by the Animal Care Committee of Concordia University. 
Adult male Wistar rats (275–300 g) and bilaterally adrenalectomized 
Wistar rats were purchased from Charles River 
Breeding Laboratories. All animals had ad libitum access to food 
and water. Adrenalectomized rats were given saline solution 
(0.9% NaCl) as a drinking fluid. Rats were housed individually 
in clear plastic cages equipped with running wheels. The cages 
were housed in ventilated, sound- and light-tight isolation chambers 
equipped with a computer-controlled lighting system (VitalView, 
Mini-Mitter, Sunriver, OR). Wheel-running activity 
data were recorded with VITALVIEW software (Mini-Mitter) and 
analyzed with CIRCADIA, as described in ref. 18. 
Surgery. Rats were anesthetized with a ketamine (100 mg ml)  
xylazine (20 mg ml) mixture given i.p. (1.5 ml kg). Electrolytic 
lesions, aimed at the SCN (1.2 mm posterior to the bregma, 1.9 
mm lateral to the midline, and 9.4 mm below the surface of the 
skull, at a 10° angle) were made by passing 2 mA of current for 
15 seconds through stainless steel electrodes (0.28 mm in diameter), 
insulated except for the tip, using a Grass lesion maker 
(DC LM5A, Grass Instruments, Quincy, MA). Loss of circadian 
locomotor activity rhythms in lesioned rats was determined from 
the wheel-running records obtained over 60 days by using 
periodgram analysis (CIRCADIA). 
Tissue Preparation. Rats were injected with an overdose of sodium 
pentobarbital (100 mg kg) and were perfused intracardially with 
300 ml of cold saline (0.9% NaCl) and then 300 ml of cold 4% 
paraformaldehyde in a 0.1 M phosphate buffer (pH 7.3). After 
perfusion, brains were postfixed in 4% paraformaldehyde and 
stored at 4°C overnight. Serial coronal brain sections (50  m) 
were collected from each animal by using a vibratome. 
Immunocytochemistry. Free-floating sections were washed in cold 
50 mM Tris-buffered saline (TBS) (pH 7.6) and incubated at 
room temperature for 30 min in a quenching solution made of 
TBS and 3% (wt wt) hydrogen peroxide (H2O2). After the 
quenching phase, sections were rinsed in cold TBS and incubated 
for 1 h at room temperature in a preblocking solution made of 
0.3% Triton X-100 in TBS (Triton-TBS), 3% normal goat serum, 
and 5% milk buffer. After the preblocking phase, sections were 
transferred directly into an affinity-purified rabbit polyclonal 
antibody raised against PER2 (Alpha Diagnostic International, 
San Antonio, TX) diluted 1:1,000 with a solution of Triton-TBS 
with 3% normal goat serum in milk buffer. Sections were 
incubated with the primary antibody for 48 h at 4°C. After 
incubation in the primary antibody, sections were rinsed in cold 
TBS and incubated for 1 h at 4°C with a biotinylated anti-rabbit 
IgG made in goat (Vector Laboratories) diluted 1:200 with 
Triton-TBS with 2% normal goat serum. After incubation with 
secondary antibody, sections were rinsed in cold TBS and 
incubated for 2 h at 4°C with an avidin–biotin–peroxidase 
complex (Vectastain EliteABC Kit, Vector Laboratories). After 
incubation with the ABC reagents, sections were rinsed with 
cold TBS, then rinsed with cold 50 mM Tris HCl (pH 7.6), and 
finally rinsed for 10 min with 0.05% 3,3 -diaminobenzidine 
(DAB) in 50 mM Tris HCl. Sections were then incubated on an 
orbital shaker for 10 min inDAB Tris HCl with 0.01%H2O2 and 
8% NiCl2.After this final incubation, sections were rinsed in cold 
TBS, wet-mounted onto gel-coated slides, dehydrated through a 
series of alcohols, soaked in Citrisolv (Fisher), and coverslipped 
with Permount (Fisher). 
Data Analysis. Stained brain sections (14–20 sections per area for 
each rat) were examined under a light microscope, and images 
were captured under 20 magnification by using an XC-77 video 
camera (Sony, Tokyo), an LG-3 frame grabber (Scion, Frederick, 
MD), and NIH IMAGE 1.63 software. Cells immunopositive for 
PER2 were counted manually on the captured images by using 
a 400   400- m template for the CEA and BLA and a 200   
400- m template for the DG. Within the DG, the template was 
placed horizontally over the CA3 region. The estimate of the 
number of PER2 immunoreactive cells per region was calculated 
from the counts of the 10 images showing the highest number of 
labeled nuclei unilaterally. Differences between groups were 
revealed with ANOVA. The significance threshold was set at 
0.05 for all analyses. 
Results 
Two Daily Patterns of PER2 Expression. The expression of PER2 in 
the CEA, BLA, and DG was assessed in rats that were housed 
under a 12 h:12 h light–dark cycle (300 lux at cage level) for at 
least 20 days and killed at one of eight equally spaced zeitgeber 
times (ZTs) (ZT0 denotes time of light on) over the day and 
night (n 4 per time point).Asignificant daily rhythm of nuclear 







Fig. 1. Expression profiles of PER2 immunoreactivity in the CEA, BLA, and CA3 
regions of the DG of rats killed at ZT1 or ZT13. (Scale bars: 200  m.) CP, 
caudoputamen; LA, lateral nucleus of the amygdala; SI, substantia innominata; 
CEAl, central nucleus of the amygdala, lateral part; CEAm, central nucleus of the 
amygdala, medial part; BMAa, basomedial nucleus of the amygdala, anterior 









time of peak expression differed. In the CEA, PER2 was 
expressed primarily in the lateral subregion of the nucleus (Fig. 
1). Expression was maximal at the beginning of the dark phase 
of the entraining photocycle (at ZT13) and minimal at ZT1, the 
onset of the light phase (Figs. 1 and 2). This daily pattern is 
identical to that seen previously in the BNST-OV and SCN of 
these same rats (18), demonstrating that the CEA, BNST-OV, 
and SCN exhibit synchronous rhythms in expression of PER2. In 
the BLA complex, the distribution of expression was fairly 
uniform, whereas in the DG, expression was greatest in pyramidal 
cell layer. In contrast to the CEA, PER2 expression in the 
BLA and DG was maximal at the beginning of the light phase (at 
ZT1) and minimal at ZT13 (Figs. 1 and 2). Thus, two synchronous 
but diametrically opposite rhythms in PER2 expression 
were revealed, one in the CEA and BNST-OV and the other in 
the BLA and DG. 
The SCN Controls PER2 Oscillations in the CEA, BLA, and DG. There is 
considerable evidence that the SCN plays a key role in the 
regulation of circadian rhythms in Per gene expression in the 
brain and periphery in rats and mice (11, 13, 30). Furthermore, 
we reported previously that SCN lesions that abolished circadian 
locomotor activity rhythms blunted the rhythm in PER2 expression 
in the BNST-OV, whereas incomplete lesions that were 
without effect on circadian locomotor activity rhythms had no 
effect on PER2 expression in the BNST-OV (18). The results of 
the present analyses were similar; lesions that abolished circadian 
locomotor activity rhythms abolished PER2 rhythms in the 
CEA, BLA, and DG, whereas SCN lesions that had no effect on 
locomotor activity rhythms had no effect on PER2 rhythms in 
these regions (Fig. 3). These results show that, as is the case with 
the BNST-OV, the rhythms in PER2 expression in the CEA, 
BLA, and DG depend on the functional integrity of the SCN 
clock as determined by its ability to drive circadian locomotor 
activity rhythms. 
PER2 Oscillation in the CEA, BLA, and DG After Bilateral Adrenalectomy. 
Cells in the CEA, BLA, and DG express glucocorticoid 
receptors and exhibit a range of responses to endogenous and 
exogenous glucocorticoids (31–36). Here, we found that in 
adrenalectomized rats, the rhythm in PER2 in the CEA was 
abolished (F[3,18]   0.91, P   0.45) (Fig. 4). In contrast, 
adrenalectomy had no effect on PER2 expression in the BLA 
and DG. In BLA, PER2 expression was rhythmic in adrenalectomized 
rats (F[3,18]   7.34, P   0.002), and in the DG, the 
rhythm of expression approached significance (F[3,18]   2.83, 
P   0.06). These rhythms were indistinguishable from those in 
the BLA and DG of sham operated control rats (Fig. 4). These 
findings suggest that PER2 expression in these regions is differentially 
sensitive to glucocorticoids. Our previous findings showing 
that removal of the adrenal glands blunts the rhythm in PER2 
expression in the BNST-OV led us to suggest a role for adrenal 
glucocorticoid hormones in the control of PER2 oscillations in 
the BNST-OV (18). The present results show that the rhythm of 
expression of PER2 in the CEA is similarly controlled by the 
adrenal gland, whereas that in the BLA and DG are not 
influenced by adrenal hormones. 
Discussion 
The BLA and CEA are known to play distinct but integrative 
roles in the regulation of emotional state. BLA receives multimodal 
sensory input from the cortex and thalamus, and studies 
of phenomena as diverse as fear learning and drug reward 
suggest that the primary function of the BLA is to integrate 
information from conditioned and unconditioned stimuli and to 
communicate this information to areas of the brain involved in 
motivational and emotional responses (21, 23, 25). A major 
projection of the BLA is to the CEA, whose primary function is 
to gate information from the BLA, and from a host of other 
cortical and subcortical areas, to the limbic-forebrain, hypothalamic, 
and brainstem regions controlling specific endocrine, 
autonomic, arousal, and behavioral responses (37–40). Furthermore, 
there is considerable evidence that information from the 
BLA is also transmitted to the hippocampus by means of its 
projections to the entorhinal cortex and can modulate neural 
plasticity in the DG (41, 42). The BLA modulates neural 
plasticity in the DG, and this effect has been proposed as a 









Fig. 2. Mean (  SEM) number of PER2-immunoreactive nuclei in the CEA, 
BLA, and CA3 regions of the DG of rats killed at different ZTs (n   4 per time 
point). Cells immunopositive for PER2 were counted manually by using a 400  
400- m template for the CEA and BLA and a 200   400- m template for the 
DG. The number of PER2 immunoreactive cells per region was calculated for 











Fig. 3. Mean( SEM) number of PER2-immunoreactive nuclei in the CEA, BLA, 
andCA3regions of theDGof SCN-lesioned rhythmic and SCN-lesioned arrhythmic 






ory processes (28, 29, 43). Several transmitter systems and 
hormones and a large number of cellular and molecular mechanisms 
have been proposed to control and modulate neural 
transmission and plasticity within each of these regions (44). In 
the present study, we found that cells in the CEA, BLA, and DG 
exhibit daily rhythms in expression of the clock protein PER2, a 
key component of the molecular oscillator generating circadian 
rhythms in cells and tissues of mammals (45, 46). Our finding of 
circadian oscillations of PER2 in the CEA, BLA, and DG adds 
a previously unrecognized level of complexity to the control and 
modulation of activity within these regions. 
We identified two temporally distinct patterns of PER2 expression: 
one in the CEA, where expression peaks in the evening, 
and one in the BLA and DG, where expression peaks in the 
morning. Significantly, PER2 expression in the CEA is confined 
to the lateral part of the nucleus, which closely resembles the 
cytoarchitecture and chemoarchitecture of the BNST-OV (19, 
47–50). Furthermore, the circadian pattern of PER2 expression 
in the CEA is identical to that which we found previously in the 
BNST-OV (18). In contrast, the patterns of expression in the 
BLA and DG resemble those that we have observed in other 
hippocampal subregions and in cortical areas such as the cingulate, 
entorhinal, piriform, and insular cortices (data not 
shown). 
The two diametrically opposite rhythms observed in the CEA 
and BNST-OV and in the BLA andDGwere similarly controlled 
by the SCN clock, as shown by the finding that lesions of the SCN 
that abolished circadian locomotor activity rhythms also abolished 
the rhythms of PER2 expression. Indirect projections from 
the SCN to these regions by means of, for example, the paraventricular 
nucleus of the thalamus, have been described and 
could carry circadian information to these structures (51, 52). 
Loss of PER2 rhythmicity in the CEA, BLA, and DG after 
functional disruption of the SCN clock suggests that rhythmic 
expression of PER2 in these structures is driven by the SCN. 
Alternatively, the SCN may function merely as a synchronizer of 
rhythms generated in these regions by multiple self-sustaining 
cellular circadian oscillators (53). 
Another important finding, and one with particular significance 
to the regulation of circadian oscillations within these 
regions, is that the rhythms in PER2 expression were differentially 
sensitive to adrenalectomy. As previously reported for the 
BNST-OV (18), the rhythm in PER2 in the CEA depended on 
the presence of the adrenal glands, whereas the rhythms in the 
BLA and DG were unaffected by adrenalectomy. The finding 
that the PER2 expression in the CEA and BNST-OV is abolished 
by adrenalectomy suggests that the rhythm of PER2 is modulated 
by glucocorticoids, which is consistent with evidence that Per 
gene expression in peripheral tissues is sensitive to glucocorticoids 
(54, 55). Furthermore, these regions contain high densities 
of glucocorticoid receptors, and glucocorticoids are known to 
modulate cell morphology and the expression of peptides such as 
corticotropin-releasing factor (CRF) and enkephalin (ENK) in 
these regions (31, 56–62). Preliminary evidence indicates that 
corticosterone added to the drinking water can restore PER2 
rhythms in the CEA and BNST-OV of adrenalectomized, SCNintact 
rats. It is important to note, however, that we have yet to 
determine whether the presence of corticosterone in itself is 
permissive or whether it is the rhythm of intake that brings about 
this effect. An additional observation that we made is that cells 
within the CEA and BNST-OV that express PER2 are immunoreactive 
to ENK but not to CRF. This observation is interesting 
in light of findings that ENK cells of the CEA and 
BNST-OV are particularly sensitive to the effect of stressors and 
drugs as assessed by c-fos gene expression (63–65). 
Contrary to the CEA and BNST-OV, the rhythm of PER2 
expression in the BLA and DG was insensitive to adrenalectomy. 
This finding is surprising, given the overwhelming evidence of 
the importance of these regions in the effects of glucocorticoids 
on physiology and behavior. For example, although the BLA has 
only a moderate level of glucocorticoid receptors, it has been 
shown that it is critical for the effect of corticosterone on 
emotional memory (66). The hippocampus contains high levels 
of glucocorticoid receptors and is well known for its role in 
stress-induced corticosterone-mediated feedback regulation of 
the hypothalamic–pituitary–adrenal (HPA) axis (34, 67). Thus, 
in these regions, there appears to be a dissociation between the 
effect of glucocorticoids on memory processes and the regulation 
of the HPA axis and its effects on PER2 expression. 
The current view of circadian organization in mammals is that 
rhythms are controlled by a hierarchical system of circadian 
oscillators in the brain and periphery that are subordinate to, or 
enslaved by, the master clock in the SCN (68). Although the 
function of specific subordinate oscillators is yet to be determined, 
it is assumed that they serve to gate information from the 
master clock into tissue-specific rhythmic outputs. In accordance 
with these ideas, we propose that the cell groups that exhibit 
rhythms in PER2 expression that we have identified in the 
amygdala, BNST, and hippocampus are strategically situated to 
play a role in the circadian modulation of processes normally 
mediated by these regions. Furthermore, we propose that disturbances 
of the coupling between the master clock and these 
cell groups, such as those we have observed after adrenalectomy 
and after shifts in the entraining light cycle, will affect emotional 
state and cognitive functioning. Finally, our findings may suggest 
a mechanism to explain how stressful experiences and changes in 
emotional state can act downstream from the SCN to affect 
specific behavioral and physiological circadian rhythms. 
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Fig. 4. Mean (  SEM) number of PER2-immunoreactive nuclei in the CEA, BLA, 
and CA3 regions of the DG of adrenalectomized and sham operated rats as a  
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